Modus Therapeutics Holding AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was SEK 9.36 million compared to SEK 12.29 million a year ago. Basic loss per share from continuing operations was SEK 0.58 compared to SEK 0.76 a year ago.
For the full year, net loss was SEK 18.32 million compared to SEK 20.69 million a year ago. Basic loss per share from continuing operations was SEK 1.14 compared to SEK 1.67 a year ago.